Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) said its Epinephrine Hydrochloride Injection passed China's National Medical Products Administration's consistency of quality and efficacy evaluation, a Thursday Hong Kong bourse filing said.
The drug is mainly suitable for treating severe dyspnea caused by bronchospasm, can quickly relieve anaphylactic shock caused by medication, and can be used to prolong the action time of infiltration anesthesia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments